Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Geron Corporation

WAYNE, Pa., March 26, 2014 /PRNewswire/ -- Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of purchasers the securities of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) between June 16, 2013 and March 11, 2014, inclusive (the "Class Period").

For more information regarding this class action suit, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/gern

The complaint charges Geron and certain of its executives with violations of federal securities laws.  Specifically, the complaint alleges that Geron misrepresented and/or failed to disclose: (1) persistent low-grade liver function test abnormalities had been observed in the Phase 2 study of its drug imetelstat in essential thrombocythemia or polycythemia vera patients; (2) there was a high risk of potential chronic livery injury following long-term exposure to the drug, and (3) as a result of the foregoing, defendants' positive statements about the prospects for imetelstat lacked a reasonable basic and/or were materially false and misleading.

On March 12, 2014, the Company announced it had received a verbal notice from the U.S. Food and Drug Administration ("FDA") that a clinical hold would be placed on imetelstat clinical trials.

On this news, shares of Geron fell over 60% to close at $1.69 per share.

If you are a member of the class, you may, no later than May 13, 2014, request that the Court appoint you as lead plaintiff of the class.  A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Under certain circumstances, one or more class members may together serve as "lead plaintiff."  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.

For more information about the case or to participate online, please visit: www.rmclasslaw.com/cases/gern, or contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218, or by e-mail at rmaniskas@rmclasslaw.com.  For more information about class action cases in general or to learn more about Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.

CONTACT: 

Ryan & Maniskas, LLP


Richard A. Maniskas, Esquire


995 Old Eagle School Rd., Suite 311


Wayne, PA 19087


877-316-3218


rmaniskas@rmclasslaw.com


www.rmclasslaw.com/cases/gern

Logo - http://photos.prnewswire.com/prnh/20121112/MM11729LOGO

SOURCE Ryan & Maniskas, LLP



RELATED LINKS
http://www.rmclasslaw.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.